Meeting
2018 Genitourinary Cancers Symposium
Contemporary trends in abiraterone and enzalutamide prescription by provider specialty.
Authors
Daniel Pucheril
Brigham and Women’s Hospital, Boston, MA
Daniel Pucheril , Ye Wang , Dimitar V. Zlatev , Paul L. Nguyen , Adam S. Kibel , Steven Lee Chang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 366)
DOI
10.1200/JCO.2018.36.6_suppl.366
Abstract #
366
Poster Bd #
E13
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Quality Care Symposium
Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D.
First Author: Megan Veresh Caram
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES).
First Author: Karim Fizazi
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
First Author: Mehmet Asim Bilen
Poster
2024 ASCO Genitourinary Cancers Symposium
Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.
First Author: Bobby Chi-Hung Liaw